Journal
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Volume 20, Issue 3, Pages 350-356Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00004714-200006000-00010
Keywords
-
Categories
Ask authors/readers for more resources
Cognitive dysfunction occurs in up to 65% of patients with multiple sclerosis (MS), but there is no effective treatment for the symptoms. The authors conducted a 12-week, open-pilot study to assess the efficacy and tolerability of donepezil HCl administered in patients with RIS and cognitive impairment. Seventeen patients at a long-term care facility with Mini-Mental State Examination scores of less than or equal to 25 received 5 mg of donepezil HCl for a 4-week period, followed by 8 weeks of 10 mg of donepezil HCl. Cognitive, neurologic, functional, and behavioral assessments were conducted at baseline and at 4 and 12 weeks. Statistically significant improvement was observed in several cognitive domains including attention, memory, and executive functioning, as well as different aspects of behavior, These data suggest that donepezil HCl merits further study as a potentially viable treatment option for patients with cognitive impairment associated with MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available